Donald Trump's remarks unacceptable, offensive: Wife

Beijing, May 18: China has reported 25 new COVID-19 patients, the health authorities said on Monday, as 14 asymptomatic cases were detected in Wuhan, the first epicentre of the coronavirus where officials are doing mass testing of the city's entire 11 million population, taking the number of such cases in the city to 337, the highest in the country.

The death toll in China remained at 4,634 on Sunday with no new fatalities reported.

China's National Health Commission (NHC) reported seven new confirmed cases of COVID-19 and 18 asymptomatic cases on Sunday.

Jilin province where the government has implemented strict control measures in the last few days following reports of clusters of cases in Jilin city reported two cases on Sunday, while Shanghai city has reported one.

As of Sunday, the overall confirmed cases in China had reached 82,954, including 82 patients who are still being treated, and 78,238 people who have been discharged after recovery.

Also on Sunday, 18 new asymptomatic cases including two from abroad were reported in China, taking the total number under medical observation to 448, the NHC said.

Asymptomatic cases pose a problem as the patients are tested COVID-19 positive but develop no symptoms such as fever, cough or sore throat. However, they pose a risk of spreading the disease to others.

Wuhan which is undergoing mass testing of the city's entire over 11 million population to determine the prevalence of the virus has reported no new confirmed cases, but 14 new asymptomatic infections, taking the number of such cases in the city to 337, the highest in the country, according to the figures released by the local health commission on Sunday.

The death toll in Hubei province stood at 4,512, including 3,869 in Wuhan.

The province so far has reported 68,134 confirmed COVID-19 cases in total, including 50,339 in Wuhan, according to the officials figures.

As the cases dropped, China on Sunday exempted people in Beijing from wearing masks, signalling that the virus is under control in the national capital.

As the virus is abating in the country, China is opening up all its business including entertainment centres like Shanghai Disneyl and to show that it has managed to control the dreaded virus while the world is struggling with it with lockdowns and massive casualties.

The novel coronavirus which originated in Wuhan in December last year has claimed 315,185 lives and infected over 4.7 million people globally, according to Johns Hopkins University data.

Beijing, Mar 25: Around 5,000 people have signed up for the phase I clinical trial of recombinant novel coronavirus vaccine in Chinese city Wuhan where the virus first emerged late last year.

The recruitment for participants ended this week with nearly 5,000 volunteers signing up for the trial, state-run Beijing News reported on Wednesday.

A single-centre, open and dose-escalation phase I clinical trial for recombinant novel coronavirus vaccine (adenoviral vector) will be tested in healthy adults aged between 18 and 60 years, according to the ChiCTR (China Clinical Trial Register).

The trial, led by experts from the Academy of Military Medical Sciences, gained its approval on March 16 and the research is expected to last half a year.

Requiring at least 108 participants, the trial will be conducted in Wuhan, capital of Hubei province, the region worst-affected by the virus in the country, state-run China Daily reported.

Participants will experience 14-day quarantine restrictions after being vaccinated and their health condition will be recorded every day.

Chinese scientists are hastening the development of COVID-19 vaccines through five approaches --- inactivated vaccines, genetic engineering subunit vaccines, adenovirus vector vaccines, nucleic acid vaccines and vaccines using attenuated influenza virus as vectors.

So far, most teams are expected to complete preclinical research in April and some are moving forward faster, Wang Junzhi, an academician with the Chinese Academy of Engineering said.

Wang noted that research and development of COVID-19 vaccines in China is not slower than foreign counterparts and has been carried out in a scientific, standardised and orderly way.

China has stepped up the process to finalise vaccines to counter COVID-19 after Kaiser Permanente research facility in Seattle and Washington stole the march and began human trials.

China lifted tough restrictions on the Hubei province on Wednesday after a months-long lockdown as the country reported no new domestic cases.

But there were another 47 imported infections from overseas, the National Health Commission said. In total, 474 imported infections have been diagnosed in China -- mostly Chinese nationals returning home.

Manila, Apr 13: The Asian Development Bank (ADB) on Monday tripled the size of its response to novel coronavirus disease (COVID-19) pandemic to 20 billion dollars and approved measures to streamline its operations for quicker and more flexible delivery of assistance.

The package expands ADB's 6.5 billion dollars initial response announced on March 18, adding 13.5 billion dollars in resources to help ADB's developing member countries counter the severe macroeconomic and health impacts caused by COVID-19.

The 20 billion dollar package includes about 2.5 billion dollars in concessional and grant resources.

"This pandemic threatens to severely set back economic, social, and development gains in Asia and the Pacific, reverse progress on poverty reduction and throw economies into recession," said ADB President Masatsugu Asakawa.

"Our expanded and comprehensive package of assistance, made possible with the strong support of our board, will be delivered more quickly, flexibly and forcefully to the governments and the private sector in our developing member countries to help them address the urgent challenges in tackling the pandemic and economic downturn," he said in a statement.

ADB's most recent assessment released on April 3 estimates the global impact of the pandemic at between 2.3 and 4.8 per cent of gross domestic product. Regional growth is forecast to decline from 5.2 per cent last year to 2.2 per cent in 2020.

The new package includes the establishment of a COVID-19 pandemic response option under ADB's countercyclical support facility.

Up to 13 billion dollars will be provided through this new option to help governments of developing member countries implement effective countercyclical expenditure programs to mitigate impacts of the COVID-19 pandemic, with a particular focus on the poor and the vulnerable.

Grant resources will continue to be deployed quickly for providing medical and personal protective equipment and supplies from expanded procurement sources.

Some 2 billion dollars from the 20 billion dollar package will be made available for the private sector. Loans and guarantees will be provided to financial institutions to rejuvenate trade and supply chains.

Enhanced microfinance loan and guarantee support and a facility to help liquidity-starved small and medium-sized enterprises, including those run by female entrepreneurs, will be implemented alongside direct financing of companies responding to or impacted by COVID-19.

The response package includes a number of adjustments to policies and business processes that will allow ADB to respond more rapidly and flexibly to the crisis. These include measures to streamline internal business processes, widen the eligibility and scope of various support facilities and make the terms and conditions of lending more tailored.

All support under the expanded package will be provided in close collaboration with international organisations, including the International Monetary Fund, World Bank Group, World Health Organisation, UNICEF, other UN agencies and the broader global community.